MAGEA3 and non-small cell lung carcinoma: BNT116, a uridine RNA-based lipoplex vaccine encoding 6 TAA mRNAs (MAGEA3, CLDN6, KK-LC-1, PRAME, MAGEA4, and MAGEC1) began a first-in-human clinical trial in 2022 (LuCa-MERIT-1) recruiting 20 advanced NSCLC patients who have progressed on anti-PD1/PD-L1 and a platinum-based chemotherapy (NCT05142189) [168].